SYDNEY, March 6, 2015 /PRNewswire/ -- Novogen today
announces that Professor Gil Mor MD
PhD from Yale Medical School will be
presenting pre-clinical data on the lead candidate product,
Cantrixil, at two upcoming conferences.
The first is an oral presentation at the
62nd Society of Reproductive Investigation
conference, March 25-28, Hilton
San Francisco, CA. Professor Mor's
presentation will focus on the pre-clinical efficacy studies that
justified the Company's decision to progress Cantrixil into the
clinic for the treatment of abdominal carcinomatosis.
The second is a late-breaking poster at the annual American
Association for Cancer Research (AACR) conference, April 18-22, Pennsylvania Convention Center, Philadelphia, PA. The presentation will review
mechanistic aspects of Cantrixil efficacy in ovarian cancer stem
cells, and also detail in vivo data generated on Cantrixil in
Yale's recurrent ovarian cancer
carcinomatosis model that has informed the design of the Company's
first-in-man clinical trial.
About Novogen Limited
Novogen is a public, drug-development company whose shares trade
on both the Australian Securities Exchange ('NRT') and NASDAQ
('NVGN'). The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc.,
with Yale University.
Novogen has two Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM
compounds target the microfilament component of the cancer cell and
when used in conjunction with standard anti-microtubular drugs,
result in comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant
ascites, prostate cancer, neural cancers (glioblastoma,
neuroblastoma in children) and melanoma are the key clinical
indications being pursued, with the ultimate objective of employing
both technologies as a unified approach to first-line therapy.
Further information is available on our website www.novogen.com.
For more information please contact:
Corporate
Contact
Dr. Graham
Kelly
Executive Chairman
& CEO
Novogen
Group
Graham.Kelly@novogen.com
+61 (0) 2 9472
4100
|
Media
Enquiries
Cristyn
Humphreys
Chief Operating
Officer
Novogen
Group
Cristyn.Humphreys@novogen.com
+61 (0) 2 9472
4111
|
Forward Looking Statement
This press release contains "forward-looking statements"
within the meaning of section 27A of the Securities Act of 1933 and
section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "appear," "intends," "hopes,"
"anticipates," "believes," "could," "should," "would," "may,"
"target," "evidences" and "estimates," and other similar
expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are
not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug
development program, including, but not limited to, CANTRIXIL, and
any other statements that are not historical facts. Such
statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to the
difficulties or delays in financing, development, testing,
regulatory approval, production and marketing of the Company's drug
components, including, but not limited to CANTRIXIL, the ability of
the Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy
of the Company's drug compounds, including, but not limited to,
CANTRIXIL, that could slow or prevent products coming to market,
the uncertainty of patent protection for the Company's intellectual
property or trade secrets, including, but not limited to, the
intellectual property relating to CANTRIXIL, and other risks
detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on
Form 20-F and its reports on Form 6-K. Such statements are based on
management's current expectations, but actual results may differ
materially due to various factions including those risks and
uncertainties mentioned or referred to in this press
release. Accordingly, you should not rely on those
forward-looking statements as a prediction of actual future
results.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cantrixil-data-to-be-presented-at-two-major-conferences-300046599.html
SOURCE Novogen Ltd